[NCI CIRB] S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
This 2-arm randomized study designed to explore if standard systemic therapy plus definitive treatment of the primary cancer improves disease control and survival over standard systemic therapy alone.
Metastatic Prostate Cancer
Adenocarcinoma of the prostate
Intact prostate with no prior local therapy
Radiographic evidence of disease progression in bone or soft tissue
Castration resistant (Testosterone less than 50 ng/dL)
18 - 110
Healthy Volunteers Needed
Duration of Participation
Up to 8 years and 7 months.